Payment overview · 2025
General Payments
$305.10
15 reported records · 9 companies
Healthcare provider profile · identity verified
John Patrick Mccullough, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · KNOXVILLE, TN · NPI 1538854658
Verified facts
What the public records show
CMS Open Payments records show John Patrick Mccullough, FNP-C received $305.10 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.06 | 30.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.15 | 15.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.64 | 15.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.33 | 9.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.75 | 7.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.43 | 6.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.96 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.12 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.66 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.10 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.06 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.15 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Fluticasone Propionate | Fluticasone Propionate | 179 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 154 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 99 | 45 |
| Gabapentin | Gabapentin | 92 | 38 |
| Losartan Potassium | Losartan Potassium | 86 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 45 |
| Lisinopril | Lisinopril | 79 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 66 |
| Furosemide | Furosemide | 66 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 24 |
| Methylprednisolone | Methylprednisolone | 45 | 43 |
| Omeprazole | Omeprazole | 43 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 43 |
| Potassium Chloride | Potassium Chloride | 43 | 16 |
| Azithromycin | Azithromycin | 41 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 17 |
| Metformin Hcl | Metformin Hcl | 40 | 16 |
| Montelukast Sodium | Montelukast Sodium | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 39 |
| Prednisone | Prednisone | 40 | 40 |
| Famotidine | Famotidine | 39 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 13 |
| Cefdinir | Cefdinir | 35 | 35 |
| Tramadol Hcl | Tramadol Hcl | 35 | 16 |
| Alprazolam | Alprazolam | 34 | 15 |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 17 |
| Carvedilol | Carvedilol | 31 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | 13 |
| Sertraline Hcl | Sertraline Hcl | 26 | 11 |
| Valsartan | Valsartan | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 21 |
| Ondansetron Odt | Ondansetron | 23 | 22 |
| Simvastatin | Simvastatin | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Estradiol | Estradiol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.10 · 15 records | ABBVIE INC. | AREXVY, ENHERTU, GVOKE HYPOPEN, KRYSTEXXA, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error